Brevets américains et européens pour la lame innovante CellKeep™
Pour diffusion immédiate | 22 Avril 2024 |
ANGLE plc ("la Société")
US AND EU PATENTS FOR ANGLE'S INNOVATIVE CELLKEEP™ SLIDE
Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that the European Patent Office has granted a European Patent for its innovative CellKeep™ slide. A formal communication has also been received from the United States Patent and Trademark Office indicating that grant of the equivalent US patent application is imminent.
The proprietary CellKeep slide is the result of a three-year development effort by ANGLE to address CTC loss endemic in standard laboratory microscopy techniques for the cytological analysis of CTCs. The result is a new device and method to attach cells to the slide, which extensive inhouse testing has demonstrated, eliminates over 70% of CTC loss experienced when using standard techniques.
Le Parsortix® system efficiently captures CTCs from blood and these remain intact and viable (live) prior to downstream analysis. When visualising CTCs by microscopy there is a critical step to transfer CTCs to a slide for biomarker labelling. In-house testing has shown that standard laboratory techniques, used worldwide, result in a high rate of cell loss (>50%) and cause damage to CTCs. Reducing cell loss to a minimum is critical for subsequent analysis of CTCs as they are present in very low numbers in the blood.
ANGLE has developed the CellKeep slide to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells. The technique also reduces costs by concentrating the CTCs into a smaller area on the slide, thereby limiting the quantity of high-cost antibodies and imaging time required to identify and analyse cells.
In analytical studies, CTCs were harvested from duplicate cancer patient blood samples and deposited on either standard microscope slides or ANGLE's new CellKeep slides, then processed and stained for CTC biomarkers. The study demonstrated that the use of CellKeep slides significantly increased the identification of CTCs with higher sample positivity rates, and better preservation of CTC morphology and clusters.
The new CellKeep slide is an integral part of ANGLE's Portrait®+ CTC staining kit which is available for customers to identify and enumerate CTCs harvested using the Parsortix system.
Le PDG d'ANGLE, Andrew Newland, a commenté :
"We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions. Following harvesting of rare CTCs from patient blood samples using the Parsortix system, the CellKeep slide and associated methodology will significantly improve the capture of CTCs for microscopy-based biomarker assays and will enhance sensitivity across ANGLE's assay portfolio. This is a significant technology advancement for the CTC liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer.
ANGLE Chief Scientific Officer, Karen Miller commented:
"We are pleased to share our success in securing IP rights for ANGLE's CellKeep slide which enhances the capture of CTCs on to slides and facilitates evaluation of cancer cell biomarkers. This technology is a significant advancement over current standards for CTCs and has the potential to capture other cell types from body fluids such as blood, urine or cerebrospinal fluid, for subsequent analysis.
Pour plus d'informations:
ANGLE SA | +44 (0) 1483 343434 |
Andrew Newland, directeur général Ian Griffiths, directeur financier |
|
Berenberg (NOMAD and Corporate Broker) Toby Flaux, Ciaran Walsh, Milo Bonser |
+ 44 (0) 20 3207 7800 |
FTI Consulting Simon Conway, Ciara Martin Matthew Vintimille (États-Unis) |
+ 44 (0) 203 727 1000 +1 (212) 850 5624 |
Les informations contenues dans cette annonce sont considérées par la Société comme des informations privilégiées, comme stipulé dans le règlement européen sur les abus de marché (596/2014). Dès la publication de cette annonce via un service d'information réglementaire, ces informations sont considérées comme étant du domaine public.
Pour la recherche uniquement. Ne pas utiliser dans les procédures de diagnostic.
Pour les conditions fréquemment utilisées, veuillez consulter le site Web de la société sur https://angleplc.com/investor-relations/glossary/
Notes aux rédacteurs
À propos d'ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® Le système PC1 permet une analyse complète en aval de l'échantillon, y compris l'imagerie de cellules entières et l'analyse protéomique ainsi qu'une analyse moléculaire génomique et transcriptomique complète.
Les activités commerciales d'ANGLE se concentrent sur les produits de diagnostic et les services cliniques. Les produits de diagnostic incluent le Parsortix® system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratory. Services include custom assay development and clinical trial sample testing for pharma.
Plus de 90 publications évaluées par des pairs ont démontré les performances du système Parsortix. Pour plus d'informations, visitez www.angleplc.com
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.